

FIGURES

Figure 1





Figure 2




Figure 3

Figure 4

	Month 0	Month 3.0	Month 14.5	Month 15.9	Month 18.0
Placebo - Seronegative	n=1,832	n=1,817	n=1,744	n=94	n=7
Placebo - Seropositive	n=4,852	n=4,805	n=4,607	n=218	n=6
TDV - Seronegative	n=3,714	n=3,690	n=3,615	n=157	n=10
TDV - Seropositive	n=9,661	n=9,591	n=9,391	n=417	n=10



	Month 0	Month 3.0	Month 14.5	Month 15.9	Month 18.0
Placebo - Seronegative	n=1,832	n=1,827	n=1,776	n=94	n=7
Placebo - Seropositive	n=4,852	n=4,823	n=4,700	n=220	n=6
TDV - Seronegative	n=3,714	n=3,693	n=3,635	n=157	n=10
TDV - Seropositive	n=9,661	n=9,599	n=9,435	n=417	n=10

Figure 5

Study Design





Figure 6

Scheme of Trial Design (HAV + TDV Co-administration)



Month, Visit

Notes:

- (i) A blood sample for measurement of Baseline anti-HAV and bodies will be collected at Screening from all subjects.
- (ii) Blood samples for immunogenicity assessments will only be collected from subjects included in the immunogenicity subset (120 subjects in each group).
- (iii) Safety will be assessed in all subjects.